How it works
Tesamorelin is a synthetic analog of the full 44-residue human growth-hormone-releasing hormone, carrying an N-terminal trans-3-hexenoic acid cap. The modification confers resistance to DPP-4 degradation, extending half-life relative to native GHRH while preserving GHRH-receptor agonism on pituitary somatotrophs. In clinical research it is best characterized for reductions in visceral adipose tissue driven through endogenous, pulsatile GH release.
Learn more about the science →Certificate of Analysis+
LC-MS identity, HPLC purity (≥99%), mass spec confirmation against 5,135.9 g/mol, endotoxin by LAL, appearance. Third-party ISO-17025 verified.
View full certificate →Specifications+
Storage & handling+
Lyophilized: −20°C, 24 months. Reconstituted: 2–8°C, use within 14 days — like other GHRH analogs, tesamorelin is more stable lyophilized than in solution. Reconstitute with bacteriostatic water; protect from light.
We ship in insulated parcels with phase-change cooling and a tamper-evident seal.
FAQs+
How does tesamorelin differ from sermorelin?+
Both are GHRH analogs. Sermorelin corresponds to GHRH(1-29); tesamorelin is the full GHRH(1-44) sequence with a hexenoyl cap that resists DPP-4 degradation and extends half-life.
What is tesamorelin best known for in research?+
Reductions in visceral adipose tissue through endogenous GH release, characterized in clinical metabolic studies.
Why is it placed in Growth Factor Research?+
Growth Factor Research at hábit groups the growth-signaling and GHRH-axis compounds — sermorelin, CJC-1295, ipamorelin, and tesamorelin sit together there.
What's a typical reconstitution concentration?+
Investigator-dependent. A common preparation is 2 mL bacteriostatic water per 10mg vial, yielding 5 mg/mL.
Why the shorter post-reconstitution window?+
GHRH analogs are more labile in solution. A 14-day window at 2–8°C minimizes potency loss.
Is tesamorelin subscription-eligible?+
Yes. 15% off on a 60-day cycle.
The research behind this compound, cited in full.
Provided for context only. None of the studies cited below evaluate hábit material specifically; they document the published literature on the compound and its mechanism. Research-use claims are not therapeutic claims.
- [01] Falutz J. et al. N Engl J Med 357 (2007): 2359–2370.
- [02] Stanley TL. et al. JAMA 312 (2014): 380–389.
- [03] Ferdinandi ES. et al. Basic Clin Pharmacol Toxicol 100 (2007): 49–58.
- [04] Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation
Verified buyer notes
Initials only — every quote is verified against an order record. We don’t ghost-write reviews.
“COA matched what we ran in-house. Powder reconstituted clean, no haze. Did exactly what we needed it to.”
“Switched after two bad lots from a previous source. Three orders in, zero issues.”
“Asked support a purity question and got the raw HPLC trace back within the hour. That transparency is why we reorder.”